CA
NZ
UK
AU
IND
US
Celcuity Inc. (NASDAQ: CELC) has successfully completed a convertible note offering totaling $575 million, significantly enhancing its financial resources. The net proceeds from this transaction stand at $557.2 million and are critical for funding operational growth and supporting strategic initiatives. Of these funds, $137 …
CV Sciences, Inc. (OTC: CVSI) reported revenue of $3.0 million for the quarter ended June 30, 2026, reflecting a 17.5% decline from $3.6 million recorded during the same quarter last year. This decline arose from decreased salesVolumeattributed to ongoing challenges from restrictive federal regulations …
Aktis Oncology, Inc. (NASDAQ: AKTS) has announced a net loss of $24.1 million for the second quarter of 2026, representing a significant increase of $6.0 million from $18.1 million reported during the same quarter last year. The rise in net loss can be attributed …
Annexon secured a $200 million credit facility, stretching its cash runway to 2028 and providing the funding needed to advance its late‑stage gene‑therapy and GBS programs. The infusion ofCapitaleases financing constraints ahead of the key month‑15 readout for the ARCHER II Phase III trial …
Aptevo Therapeutics Inc. (NASDAQ: APVO) has announced its intention to issue warrants covering 4.3 million shares, a proposal that remains pending until it secures the approval of its shareholders. The contemplated warrants would function as detachableOptionsthat grant holders the right to acquire common stock …
Assembly Biosciences (NASDAQ: ASMB), Inc. has announced a significant financial milestone by completing $115 million in financing aimed at bolstering its pipeline programs. Investors can view this as a key moment that strengthens the company’s financial foundation while enabling the continuation of critical clinical …
Assembly Biosciences, a biotechnology firm focused on innovative treatments for serious viral and liver diseases, has announced a critical $115 million financing round designed to advance its clinical programs, particularly for ABI-6250, which is expanding into cholestatic liver diseases like primary biliary cholangitis and …
The update comes at a key moment as investors are keen to understand how the company is managing current market conditions. These results will serve as a key indicator of Atrium's financial health and strategic positioning, especially within a competitive healthcare environment. Investors typically …
Bio-key International secured $2.51 million and issued 1.24 million new warrants, while lowering the exercise price to make the instruments cheaper for investors. The added capital and more attractive warrants enhanceLiquidityand provide a clearer path forEquityconversion.
Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) reported a net loss of $3.3 million for Q2 2026. This financial result highlights ongoing operational costs faced by the firm. Even with this loss, the company remains positioned to extend its cash runway into the first quarter of …
Please wait processing your request...